Previous 10 | Next 10 |
InMed Announces Closing of US$4.5 Million Private Placement PR Newswire VANCOUVER, BC , Feb. 16 , 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medicat...
InMed Pharmaceuticals (INM): Q4 GAAP EPS of -$0.37.Cash, cash equivalents and short-term investments of $10.1M.Press Release For further details see: InMed Pharmaceuticals reports Q4 results
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results Canada NewsWire VANCOUVER, BC , Feb. 11, 2021 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company develo...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Investors will be looking to keep the focus on strong earnings reports, fiscal stimulus expectations and the impact of r...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results Canada NewsWire VANCOUVER, BC , Feb. 5, 2021 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing...
InMed Pharma (INM) has entered into definitive agreements with certain institutional investors to raise about $4.5M at a price of $4.25 per unit in a private placement.Each unit in the placement consists of one share and 0.66 of a warrant to purchase one share. Each whole warrant ha...
InMed Announces US$4.5 Million Private Placement Canada NewsWire VANCOUVER, BC , Feb. 5, 2021 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting disease...
Gainers: Tyme Technologies (TYME) +110%, GW Pharmaceuticals (GWPH) +47%, Zynerba Pharmaceuticals (ZYNE) +39%, SELLAS Life Sciences (SLS) +38%, InMed Pharmaceuticals (INM) +15%.Losers: Vaxart (VXRT) -51%, Moleculin Biotech (MBRX) -26%...
InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe PR Newswire InMed's Michael Woudenberg , Karen Long & Prof. Mauro Maccarrone among Expert Speakers VANCOUVER, BC , Jan. 19, 2021 ...
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
INM Stock Symbol:
NASDAQ Market:
InMed Pharmaceuticals Inc. Website:
InMed Pharmaceuticals (NASDAQ: INM) , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer's di...
Results confirm improvements in cognitive function, memory and locomotor activity Achieved statistical significance in certain behavioral assessments Additional molecular analyses ongoing to elucidate INM-901 mechanisms of action Vancouver, British Columbia--(Newsfile Corp. - July 30,...
Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a...